Sanofi cancer therapy FDA decision delayed

Sanofi's on-body injector cancer therapy faces a delay in its FDA review, with a decision now expected in July. The company also announced an expansion of its Tzield treatment for younger children with type 1 diabetes. This dual update highlights ongoing developments in Sanofi's pharmaceutical pipeline. While the delay for the cancer therapy introduces uncertainty, the progress with Tzield demonstrates continued efforts in addressing significant health conditions across different patient populations.